SCHEMBL3450504

SCHEMBL3450504

O=C(O)C=C1CCCc2cc(OCc3cccc(Oc4ccccc4)c3)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 9/20 0.54
MAOB P27338 9/20 0.54
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
POLB P06746 1/20 0.51
GFER P55789 1/20 0.51
PAX8 Q06710 1/20 0.51
KLF5 Q13887 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
FFAR1 O14842 6/20 0.49
FFAR4 Q5NUL3 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
RXRA P19793 2/20 0.43
RXRB P28702 2/20 0.43
RXRG P48443 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450500 1.00 MAOA (0.54) MAOAMAOBNPC1RAB9APOLB
SCHEMBL13110402 0.88 MAOA (0.48) MAOAMAOBNPC1RAB9APOLB
SCHEMBL3450181 0.83 MAOB (0.57) MAOAMAOBNPC1RAB9APOLB
SCHEMBL3450180 0.83 MAOB (0.57) MAOAMAOBNPC1RAB9APOLB
SCHEMBL3854161 0.81 MAOA (0.53) MAOAMAOBNPC1RAB9APOLB
SCHEMBL5789320 0.79 MAOA (0.51) MAOAMAOBNPC1RAB9APOLB
SCHEMBL5789323 0.79 MAOA (0.51) MAOAMAOBNPC1RAB9APOLB
SCHEMBL3450014 0.78 FFAR1 (0.53) MAOAMAOBNPC1RAB9APOLB
SCHEMBL5788075 0.74 FFAR1 (0.47) MAOAMAOBNPC1RAB9APOLB
SCHEMBL3411631 0.74 MAOB (0.57) MAOAMAOBNPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-20060258722-A1 Condensed ring compound TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) 2006-11-16 US disclosed
EP-1630152-A1 CONDENSED RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258722-A1 Condensed ring compound GPR119, GLP1R, GCGR MAOA 4002/4885MAOB 3684/4885NPC1 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.